Healthy Young AdultsNCT07821515
Does Paracetamol Influence the Release of Gut Hormones, Glucose Absorption and Glycemia?
A study testing Paracetamol in people with Healthy Young Adults and Physiology, run by University of Copenhagen at 2 sites in Denmark.
Trial summary
The study aim is to determine whether acute inhibition of endogenous prostaglandin synthesis by paracetamol affects the release of gut hormones, glucose absorption and glycemia in healthy young individuals Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Healthy Young Adults, Physiology
- What is being tested?
- Paracetamol
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 12 participants
- Where
- 2 sitesDenmark
- Study dates
- 1 Jun 2026to 31 Dec 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Age ≥ 18 years
- Nondiabetic fasting plasma glucose (< 7.0 mmol/L) at time of inclusion
- BMI of 20-25
- Written informed consent
Who cannot join
- Haemoglobin < 7.9 mmol/L
- Pregnancy or breastfeeding
- Significant gastrointestinal symptoms (e.g. dyspepsia, postprandial pain)
- Use of medication that cannot be paused for 12 hours or any drug that affects gastric emptying, small intestinal motility, glucose absorption.
- Use of paracetamol, NSAID, aspirin or similar within the previous week.
- Evidence of drug abuse, consumption of tobacco in any form or daily consumption of more than 20g alcohol
Show all 10Show fewer
- History of gastrointestinal disease, including significant upper or lower gastrointestinal symptoms, pancreatitis, or previous gastrointestinal surgery including cholecystectomy (but not uncomplicated appendicectomy)
- Participation in other research studies within the previous 3 months
- Inability to give informed consent
- Intolerance to any of the components of paracetamol and the meals used for the study
Trial locations and contacts
2 sites in 1 country. Contact the study team or a site near you to ask about taking part.
Denmark2 sites, 2 recruiting
- Recruiting
Department of Biomedical Sciences, The Panum Institute, University of Copenhagen,
Copenhagen, Capital, 2200
Simon Veedfald, MD, PhD., +45 41102595, veedfald@sund.ku.dk
Jonatan Friis, MD, jonatan.sverri.kure.friis@sund.ku.dk
- Recruiting
Hvidovre Hospital, Copenhagen University Hospital
Hvidovre, 2650
Jonatan Friis, MD, Jonatan.sverri.kure.friis@regionh.dk
About this study
The study aim is to determine whether acute inhibition of endogenous prostaglandin synthesis by paracetamol affects the release of gut hormones, glucose absorption and glycemia in healthy young individuals
- Conditions
- Healthy Young Adults, Physiology
- Being tested
- Paracetamol, Placebo
- Keywords
- prostaglandins, glucose, gut hormones, Paracetamol, GLP-1, GIP, meal test
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
ParacetamolOther
Paracetamol is used as a tool to block prostaglandin synthesis
PlaceboOther
A placebo will be administered to be able to determine the effect of paracetamol on prostaglandin synthesis
| Study group | Role | What they receive |
|---|---|---|
| Paracetamol (1000mg) | Active comparator | Not described Receives: Other: Paracetamol |
| Placebo | Placebo comparator | Not described Receives: Other: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Glucagon-like peptide 1
Plasma concentration
Measured: From baseline samples (-15, 0 min) until the end of the meal test at t = 180min
Secondary outcomes (8)
Glucose
Plasma concentration
Measured: From baseline samples (-15, 0 min) until the end of the meal test at t = 180min
Gastrin
Plasma concentration
Measured: From baseline samples (-15, 0 min) until the end of the meal test at t = 180min
Cholecystokinin
Plasma concentration
Measured: From baseline samples (-15, 0 min) until the end of the meal test at t = 180min
Glucose-dependent insulinotropic polypeptide (GIP)
Plasma concentration
Measured: From baseline samples (-15, 0 min) until the end of the meal test at t = 180min
C-peptide
Plasma concentration
Measured: From baseline samples (-15, 0 min) until the end of the meal test at t = 180min
Glucagon
Plasma concentration
Measured: From baseline samples (-15, 0 min) until the end of the meal test at t = 180min
Pancreatic polypeptide
Plasma concentration
Measured: From baseline samples (-15, 0 min) until the end of the meal test at t = 180min
3-OMG
Plasma concentration
Measured: From baseline samples (-15, 0 min) until the end of the meal test at t = 180min
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted15 Sep 2026
- Study start1 Jun 2026
- Primary completion30 Sep 2026 (estimated)
- Study completion31 Dec 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Healthy Young AdultsStudies of the same condition, open and under way.
- More trials run by University of CopenhagenThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Crossover
- Model description
- Randomised double blind placebo-controlled trial
- Masking
- Triple blind
- Who is masked
- Participant, Investigator, Outcomes assessor
- Enrolment
- 12 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University of Copenhagen
- Sponsor type
- University, hospital or other
- Collaborators
- Hvidovre University Hospital
- Responsible party
- Principal investigator, Simon Veedfald, University of Copenhagen
- Investigators
- Simon Veedfald, MD, PhD, Principal investigator, Department of BIomedical Scienes, University Copenhagen
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07821515
- Sponsor's protocol ID
- PCT-2026
- Status last verified
- Sep 2026
- First submitted
- 9 Sep 2026
- Last updated
- 15 Sep 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 15 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Does Paracetamol Influence the Release of Gut Hormones, Glucose Absorption and Glycemia?
- ClinicalTrials.gov ID
- NCT07821515
- Acronym / sponsor ID
- PCT-2026
- Conditions
- Healthy Young Adults, Physiology
- Keywords
- prostaglandins, glucose, gut hormones, Paracetamol, GLP-1, GIP, meal test
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 12 participants (estimated)
- Lead sponsor
- University of CopenhagenUniversity, hospital or other
- Collaborators
- Hvidovre University Hospital
- Study start
- 1 Jun 2026 (actual)
- Primary completion
- 30 Sep 2026 (estimated)
- Study completion
- 31 Dec 2026 (estimated)
- First posted
- 15 Sep 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The study aim is to determine whether acute inhibition of endogenous prostaglandin synthesis by paracetamol affects the release of gut hormones, glucose absorption and glycemia in healthy young individuals
Study design
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Triple blind (participant, investigator, outcomes assessor)
- Number of arms
- 2
- Model description
- Randomised double blind placebo-controlled trial
| Arm | Type | Receives |
|---|---|---|
| Paracetamol (1000mg) | Active comparator | Other: Paracetamol |
| Placebo | Placebo comparator | Other: Placebo |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- Age ≥ 18 years
- Nondiabetic fasting plasma glucose (< 7.0 mmol/L) at time of inclusion
- BMI of 20-25
- Written informed consent
Key exclusion criteria (10 listed)
- Haemoglobin < 7.9 mmol/L
- Pregnancy or breastfeeding
- Significant gastrointestinal symptoms (e.g. dyspepsia, postprandial pain)
- Use of medication that cannot be paused for 12 hours or any drug that affects gastric emptying, small intestinal motility, glucose absorption.
- Use of paracetamol, NSAID, aspirin or similar within the previous week.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| ParacetamolParacetamol is used as a tool to block prostaglandin synthesis | Other | Paracetamol (1000mg) |
| PlaceboA placebo will be administered to be able to determine the effect of paracetamol on prostaglandin synthesis | Other | Placebo |
Primary outcome
Glucagon-like peptide 1
Time frame: From baseline samples (-15, 0 min) until the end of the meal test at t = 180min
Plasma concentration
8 secondary outcomes
Glucose
Time frame: From baseline samples (-15, 0 min) until the end of the meal test at t = 180min
Gastrin
Time frame: From baseline samples (-15, 0 min) until the end of the meal test at t = 180min
Cholecystokinin
Time frame: From baseline samples (-15, 0 min) until the end of the meal test at t = 180min
Glucose-dependent insulinotropic polypeptide (GIP)
Time frame: From baseline samples (-15, 0 min) until the end of the meal test at t = 180min
C-peptide
Time frame: From baseline samples (-15, 0 min) until the end of the meal test at t = 180min
Glucagon
Time frame: From baseline samples (-15, 0 min) until the end of the meal test at t = 180min
Pancreatic polypeptide
Time frame: From baseline samples (-15, 0 min) until the end of the meal test at t = 180min
3-OMG
Time frame: From baseline samples (-15, 0 min) until the end of the meal test at t = 180min
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 15 Sep 2026.
- Individual participant dataSharing planned: No
Related trials for Healthy Young Adults
Recruiting
Effects of Red Panax Ginseng Supplementation on Cognitive Performance and Emotional Well-Being in Young Healthy Adults
Mental Acuity
Recruiting
Development of a Real-time Controller to Estimate Walking Performance Using a Bilateral Ankle Exoskeleton
Healthy Young Adults
Recruiting
Yoga vs. Stretching-Strengthening: Physical Fitness in Sedentary Young Adults
Sedentary Lifestlye, Exercise
Recruiting
Recovery After Fatigue in Young Athletes: Comparison Between TECAR Therapy and Cycle Ergometer"
Muscle Fatigue, Healthy Adult
RecruitingPhase 3
Weight Gain Prevention in Adolescents and Young Adults
Healthy Volunteers
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Simon Veedfald, MD, PhD principal investigator
Department of BIomedical Scienes, University Copenhagen
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Paracetamol in people with Healthy Young Adults and Physiology, run by University of Copenhagen at 2 sites in Denmark.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 15 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in Denmark. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Simon Veedfald, MD, PhD (+45 41102595, veedfald@sund.ku.dk), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Glucagon-like peptide 1 (time frame: From baseline samples (-15, 0 min) until the end of the meal test at t = 180min). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 Sep 2026.